Patent · US Active

Compositions and methods for treatment of cytomegalovirus

US9777043B2 · kind B2 · utility

10Cited by
3References
13Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 9, 2012
Grant dateOct 3, 2017
Priority date
Expiry dateNov 30, 2032

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2760/20245
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present disclosure provides compositions and methods useful for treating HCMV infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more HCMV epitopes, such as, for example, from HCMV envelope glycoproteins gB and/or gH and/or tegument protein pp65. Among other things, the present invention encompasses the recognition that a combination of antigens (e.g., envelope glycoproteins and structural proteins) can lead to beneficial immune responses, for example that include both a humoral response (e.g., production of neutralizing antibodies) and a cellular response (e.g., T-cell activation).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.